Continuous diagnostic operation and very positive feedback from customers

STOCKHOLM – October 24, 2023 – Inify Laboratories, a unique laboratory service that provides cancer diagnostics within pathology, has had a continuous inflow of patient samples for diagnosis, which is of paramount importance for the optimization of both the internal laboratory system and the interaction with customers.

“We have analyzed prostate biopsies on a daily basis since we opened our first laboratory in June. The feedback has been very positive, and we are experiencing an increasing interest in our services among urologists and other stake holders. The awareness about Inify Laboratories is rapidly increasing among our customer groups,” says CEO Fredrik Palm at Inify Laboratories.

What impresses most is the short response time of no more than five days. Also, the high-quality diagnostic report is seen as a major improvement with value for the customers.

“Our pathology reports, developed in-house in close collaboration with experienced urologists, are graphic and structured, making them easy to interpret which increases patient safety. The urologist clinics that send prostate biopsies to Inify Laboratories are highly satisfied with our diagnostics and response times,” says Chief Medical Officer Claes Lindh at Inify Laboratories.

Waiting times for cancer investigations are long and unpredictable, and the healthcare system is struggling to cope. Inify Laboratories is well positioned to help, offering fast, reliable diagnostics of the highest quality for all patients who need it, regardless of where they live.

“We have gathered all the necessary expertise, built and opened our laboratory, evaluated our diagnostic performance, and are now ready to offer our diagnostic services to healthcare systems on a broad scale,” says Palm.

For further information, please contact CEO Fredrik Palm, , or visit


View attachment



About Inify Laboratories

Inify Laboratories provides cancer diagnostics through ultramodern laboratory services within pathology. It uses a fully digital, standardized and AI- supported workflow to optimize quality and response times, initially within prostate. The concept is scalable and can be extended to other diagnoses.

The service includes the whole chain of sample handling: from logistics, to sample preparation, to reporting by a pathologist from either Inify Laboratories or the customer’s organization. The report is assisted by our own AI, proven in clinical studies to have world-leading accuracy. The complete workflow is supported by a tailor-made process control system.

The company, based in Sweden, became independent in 2022 through a spin-off from ContextVision, with 40 years of experience within digital imaging for medical applications. It is listed on Euronext Growth Oslo under the ticker INIFY.

This information is subject to the disclosure requirements pursuant to section 5 -12 of the Norwegian Securities Trading Act.